AbbVie Inc. $ABBV Stock Sold by Thurston Springer Miller Herd & Titak Inc.

Thurston Springer Miller Herd & Titak Inc. decreased its holdings in AbbVie Inc. (NYSE:ABBV) by 74.5% in the 3rd quarter, HoldingsChannel reports. The firm owned 1,825 shares of the company’s stock after selling 5,323 shares during the quarter. AbbVie makes up 0.8% of Thurston Springer Miller Herd & Titak Inc.’s holdings, making the stock its 21st biggest holding. Thurston Springer Miller Herd & Titak Inc.’s holdings in AbbVie were worth $477,000 as of its most recent filing with the SEC.

A number of other institutional investors have also recently made changes to their positions in the business. State Street Corp lifted its holdings in AbbVie by 1.7% during the 2nd quarter. State Street Corp now owns 82,596,748 shares of the company’s stock worth $20,784,646,000 after buying an additional 1,379,232 shares in the last quarter. Corient Private Wealth LP purchased a new position in AbbVie in the 2nd quarter valued at approximately $559,736,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in shares of AbbVie by 0.7% in the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 14,267,697 shares of the company’s stock worth $3,590,323,000 after acquiring an additional 106,091 shares in the last quarter. Legal & General Group Plc acquired a new position in shares of AbbVie in the second quarter worth $2,905,952,000. Finally, Deutsche Bank AG increased its position in shares of AbbVie by 13.0% during the second quarter. Deutsche Bank AG now owns 10,772,949 shares of the company’s stock worth $2,710,905,000 after acquiring an additional 1,241,587 shares during the period. Institutional investors and hedge funds own 70.23% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have recently issued reports on ABBV shares. Canaccord Genuity Group increased their price objective on AbbVie from $282.00 to $290.00 and gave the company a “buy” rating in a research note on Monday, August 3rd. Royal Bank Of Canada reissued an “outperform” rating and set a $280.00 target price on shares of AbbVie in a research note on Tuesday. BMO Capital Markets boosted their target price on AbbVie from $258.00 to $300.00 and gave the stock an “outperform” rating in a research note on Monday, July 13th. Guggenheim restated a “buy” rating and set a $288.00 price target on shares of AbbVie in a report on Friday, October 9th. Finally, Sanford C. Bernstein reaffirmed a “market perform” rating and issued a $225.00 price target (up from $203.00) on shares of AbbVie in a research report on Tuesday, June 23rd. One analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and six have assigned a Hold rating to the stock. According to MarketBeat, AbbVie currently has a consensus rating of “Moderate Buy” and an average price target of $277.18.

Insider Activity at AbbVie

In other news, EVP Nicholas Donoghoe sold 32,710 shares of the stock in a transaction dated Friday, August 14th. The stock was sold at an average price of $250.00, for a total value of $8,177,500.00. Following the transaction, the executive vice president owned 74,430 shares in the company, valued at approximately $18,607,500. This represents a 30.53% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 0.06% of the company’s stock.

AbbVie Price Performance

Shares of ABBV traded up $10.20 during midday trading on Wednesday, reaching $284.56. The stock had a trading volume of 1,743,498 shares, compared to its average volume of 6,390,412. The company has a market cap of $502.76 billion, a price-to-earnings ratio of 80.41, a PEG ratio of 1.28 and a beta of 0.24. The company’s fifty day simple moving average is $260.41 and its two-hundred day simple moving average is $237.87. AbbVie Inc. has a 1-year low of $190.75 and a 1-year high of $284.64.

AbbVie (NYSE:ABBV) last posted its earnings results on Friday, July 31st. The company reported $3.65 EPS for the quarter, beating the consensus estimate of $3.61 by $0.04. The firm had revenue of $16.99 billion for the quarter, compared to analyst estimates of $16.80 billion. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%. AbbVie’s revenue for the quarter was up 10.2% compared to the same quarter last year. During the same quarter in the prior year, the company posted $2.97 earnings per share. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. On average, sell-side analysts forecast that AbbVie Inc. will post 13.95 earnings per share for the current year.

AbbVie Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, November 16th. Stockholders of record on Thursday, October 15th will be given a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a dividend yield of 2.4%. The ex-dividend date of this dividend is Thursday, October 15th. AbbVie’s dividend payout ratio is currently 195.48%.

Key AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Positive SKYRIZI Crohn’s disease data: New Phase 3 AFFIRM results showed that subcutaneous SKYRIZI generated higher clinical and endoscopic response rates than placebo in adults with moderately to severely active Crohn’s disease. The data strengthen the outlook for AbbVie’s leading immunology franchise and its ability to support long-term growth. AbbVie’s Crohn’s Disease Drug SKYRIZI Shows More Positive Results
• Positive Sentiment: Growth engines remain in focus: Recent SKYRIZI and RINVOQ updates have reinforced expectations that the therapies can offset Humira’s continuing decline. RBC also expects the products, along with Vraylar, to support a potential third-quarter revenue beat. AbbVie Poised for Q3 Top-Line Beat
• Positive Sentiment: Supportive analyst backdrop: Royal Bank of Canada reaffirmed its outperform rating, while Erste Group raised its FY2027 EPS forecast to $16.34 from $16.19 and maintained a Buy rating. These actions add to investor confidence ahead of earnings.
• Neutral Sentiment: Institutional interest is mixed: Recent filings showed substantial buying by several large institutions, although other investors reduced their positions. One AbbVie executive also sold shares, but the transaction does not appear to be a central driver of the session.
• Negative Sentiment: Valuation and execution risks remain: AbbVie trades near its 52-week high, and some valuation analysis suggests the shares may be ahead of estimated fair value. Investors also remain focused on Humira erosion, competition in immunology, and the company’s elevated growth expectations.

About AbbVie

AbbVie Inc is a global biopharmaceutical company that develops, manufactures and markets medicines for a range of serious and chronic health conditions. Its portfolio spans immunology, oncology, neuroscience, eye care, aesthetics, gastroenterology and women’s health.

The company’s products include the immunology medicines Skyrizi and Rinvoq; neuroscience treatments such as Vraylar, Ubrelvy and Qulipta; and oncology medicines including Imbruvica and Venclexta. AbbVie also markets Botox Cosmetic and Botox Therapeutic, as well as other products for aesthetics, eye care and specialty care.

AbbVie was established in 2013 as an independent, publicly traded company following its separation from Abbott Laboratories.